A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S, alleging that the company made misleading statements about its growth potential stemming from its diabetes/obesity drug GLP-1. The lawsuit claims that these misrepresentations occurred between May 7, 2025 and July 28, 2025.
Investors who purchased or acquired Novo shares during this period may be eligible for compensation. To serve as a lead plaintiff, they must file papers by September 30, 2025. However, participation is not required to receive any recovery.
The law firm Bernstein Liebhard LLP represents the Class and will handle all claims on a contingency fee basis, with no upfront fees or expenses for shareholders.
Bernstein Liebhard has a proven track record of securing billions in compensation for its clients. The firm has been recognized as one of the top plaintiff’s firms by The National Law Journal and listed in The Legal 500.
Source: https://www.globenewswire.com/news-release/2025/08/04/3126946/0/en/novo-nordisk-a-s-nyse-nvo-investor-alert-investors-with-large-losses-in-novo-nordisk-a-s-should-contact-bernstein-liebhard-llp-to-discuss-their-rights.html